Management Team

President and Chief Executive Officer

Mr. Tardugno’s career has been exclusively focused in healthcare with 30 years of experience in the pharmaceutical and medical device industries. Mr. Tardugno was appointed President and Chief Executive Officer of the Company on January 3, 2007 and was elected to the Board of Directors on January 22, 2007. Prior to joining the company, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies Inc., a subsidiary of Mylan Laboratories, a transdermal drug company. He was a founding member of management of Songbird Hearing, Inc., a privately held start-up, and held the positions of Senior Vice President of Technical Operations at Bristol-Myers Squibb and Senior Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations. Mr. Tardugno holds a B.S. in Biology from St. Bonaventure University and completed the Harvard Business School executive program.

Vice President and Chief Medical Officer

Nicholas Borys, M.D. joined Celsion in October 2007 as Vice President and Chief Medical Officer. In this position Dr. Borys manages the clinical development program for Celsion. Dr. Borys, who was most recently Chief Medical Officer at Molecular Insight Pharmaceuticals, Inc., has accumulated extensive experience in all phases of pharmaceutical development with a focus in oncology while holding increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys attended Rutgers University and holds an M.D. Degree from American University of the Caribbean.

Senior Vice President, Corporate Business Strategy and Investor Relations

Jeffrey W. Church was appointed Senior Vice President, Corporate Strategy and Investor Relations on July 8, 2011. Mr. Church joined Celsion in July 2010 as Vice President and Chief Financial Officer. Mr. Church brings more than 30 years of experience in corporate finance, mergers and acquisitions, investor relations, and SEC reporting. Prior to joining the Company, Mr. Church held senior financial executive positions with several private and public clinical stage Life Science companies including Alba Therapeutics Corporation, Novavax, Inc., GenVec, Inc., and Meridian Medical Technologies, Inc. Mr. Church started his career in 1979 with the public accounting firm, Price Waterhouse. Mr. Church holds a B.S. degree from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.

Executive Director, Strategic Planning & Business Development

Raj Prabhakar joined Celsion in January 2004 and served as Director of Program Management leading the liver cancer program from preclinical stage through launch of the Phase III HEAT Study. He was promoted to his current position of Executive Director of Strategic Planning & Business Development in January 2009, after serving as Senior Director of Strategic Planning and Business Development in December 2007. Mr. Prabhakar currently heads up out-licensing and business development activities for Celsion, including managing the collaboration relationship with Yakult Honsha Co., Ltd. for the Japan Territory. He has over 10 years of biomedical industry experience including Celsion (oncology), Protiveris (proteomics), Osiris Therapeutics (stem cells) and Harvard Medical School (orthopedic research). Prior to receiving his M.B.A., Raj held analyst positions for four years in several finance, venture capital and private equity firms. In addition to 15 years of experience, Raj holds an M.B.A. from the Harvard Business School and dual B.S. degrees from MIT in biology and mechanical engineering.

Vice President, CMC and Technical Operations

Robert A. Reed, Ph.D. joined Celsion in May 2009 as Executive Director, CMC and Technical Operations. In February 2011, Dr. Reed was promoted to Vice President, CMC and Technical Operations. In this position Dr. Reed oversees the manufacturing, QA and Technical Operations functions for Celsion. He most recently was Vice President, Pharmaceutical Operations at XenoPort, Inc., has over 20 years of experience and responsibility across XenoPort, Inc., Merck & Company, Inc., and The Liposome Company, Inc., with extensive scientific and regulatory experience in the design and development of pharmaceutical products. He holds a Ph.D. in Analytical Chemistry from The University of North Carolina at Chapel Hill and was the recipient of a 3 year NIH Postdoctoral Individual Award at Princeton University.

Senior Vice President and Chief Financial Officer

Gregory Weaver joined the Company as Senior Vice President and Chief Financial Officer effective July 8, 2011. Mr. Weaver proudly served as a Director of the Company from June 2005 to July 2011. He has served as Chief Financial Officer of both public and private companies since 1992. Most recently he was Senior VP and CFO of Poniard Pharmaceuticals from 2009 to 2010, an oncology drug development company in San Francisco and Seattle. Prior to that he served as CFO of Talyst Inc. from 2007 to 2008, a pharmacy automation products and services company. In 2006 Mr. Weaver served as Senior VP and CFO of Sirna Therapeutics, an RNAI therapeutics company. From 2002 through 2005, Mr. Weaver was CFO of Nastech, a drug delivery company. From 1999 to 2002, Mr. Weaver was CFO of Ilex Oncology, Inc., an oncology drug development and contract research company, and from 1996 to 1998 he was CFO of Prism Technologies, a medical device company. Previously, Mr. Weaver, a CPA, held increasingly senior positions with Fidelity Capital in Boston and with Harte-Hanks in the publishing industry. He began his career with Arthur Andersen LLP. Mr. Weaver earned his MBA from Boston College and B.S. in accounting from Trinity University.